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http://www.diagnosticpathology.org/content/8/1/60CASE REPORT Open AccessMalignant perivascular epithelioid cell tumor of
mesentery with lymph node involvement: a case
report and review of literature
Xinge Fu1, Ju-hong Jiang1*, Xia Gu1 and Zhi Li2Abstract
Perivascular epithelioid cell tumor (PEComa) is a rare but distinct mesenchymal neoplasm composed of
histologically and immunohistochemically unique perivascular epithelioid cells. Due to its relative rarity, little is
known about the histogenesis and prognostic factors of this tumor. We describe a case of unusual mesenteric
PEComa in a 38-year-old female patient with regional lymph node involvement. Histologically, the tumor was
composed of sheet of epithelioid cells with abundant clear or eosinophillic cytoplasms. Extensive coagulative
necrosis and a few mitotic figures (2/50 high power field) could be found in tumor. The epithelioid tumor cells
were diffusely positive for HMB-45, Melan-A, and focally positive for calponin. One of enlarged mesenteric lymph
nodes was observed to be involved by tumor. A diagnosis of malignant mesenteric PEComa with lymph node
involvement was made. The patient received chemotherapy after total resection of tumor and segmental resection
of involved jejunum. There was no sign of recurrence of tumor found in period of 6-month regular follow-up after
chemotherapy. To our knowledge, this is the first case of malignant PEComa in mesentery accompanied with
regional lymph node involvement. The literature on this rare tumor is reviewed and diagnostic criteria of malignant
PEComa are discussed.
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vs/1309992178882788
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diagnosisBackground
Perivascular epithelioid cell tumor (PEComa) was first
introduced by Zamboni in 1996 to identify a group
of mesenchymal neoplasms originating from perivascular
epithelioid cells [1]. PEComa family of tumors includes
angiomyolipomas (AML), lymphangioleiomyomatosis
(LAM), clear cell “sugar” tumor (CCST) of the lung,
clear cell myomelanocytic tumor (CCMMT) of the falci-
form ligament/ligamentum teres and abdominopelvic
sarcoma of perivascular epithelioid cells [2]. PEComas
other than AML, CCST or LAM are rare. Although in-
creasingly reported over the past decade, PEComas oc-
curring in mesentery are exceedingly rare, with only 6* Correspondence: juhongjiang2006@yahoo.com
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reproduction in any medium, provided the orcases described in the literature so far [3-5]. The clinical
behavior of PEComa is not predictable, and there are no
strict histologic criteria for malignancy. Because of its
relative rarity, little is known about the natural history
and prognostic factors of PEComas, although a stratifi-
cation of PEComa of soft tissue and genitourinary tract
has been recently proposed [3,6]. Herein, we report a
PEComa of mesentery of small bowel occurring in a
middle-aged female patient with mesenteric lymph node
involvement. Although the cytologic appearance of the
tumor cells was relatively bland, the presence of exten-
sive necrosis and surrounding tissue invasion were indi-
cative of malignant behavior. To the best of our
knowledge, this is the first case of malignant mesentery
PEComa with lymph node involvement. The literature
on this rare tumor is reviewed and differential diagnosis
is discussed.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Clinical presentation and management
A 38-year-old female patient presented with complaints of
abdominal pain and abdominal distension that had
persisted 3 days before admission to our hospital. Physical
examination showed local tenderness and rebounding pain
in the left abdominal region, and decreased bowel sounds.
The laboratory results, including blood count, differential,
liver and renal function, were within the normal range.
There was no fever, weight loss and no palpable lymph-
adenopathy or organomegaly. A computed tomography
(CT) scan showed a poorly circumscribed solid mass
(9.9 cm × 8.6 cm × 7.1 cm) with mild heterogeneous
enhancement located in the left upper abdominal region
with adhesions of wall of jejunum. There was hypo-
intensity areas observed in the mass after gadolinium in-
jection (Figure 1). A preoperative presumed diagnosis was
extra-gastrointestinal stromal tumor of abdomen. The pa-
tient underwent tumor resection and segmental resection
of the jejunum. At surgery, the mass was located at the
mesentery of the small bowel and a part of the mass was
observed to extend to the wall of jejunum. The mass was
removed totally, and the postoperative phase was unevent-
ful. Since there was a possibility of tumor metastasis to an-
other anatomical location, the patient was referred to a
whole body positron emission tomography (PET)/CT
study to search for the potentially secondary tumor, but
no abnormality was found. After diagnosis, the patientFigure 1 Preoperative computed tomography (CT) scan of the
mesenteric mass. Contrast-enhanced CT demonstrating a poorly
circumscribed solid mass with mild heterogeneous enhancement
located at mesentery and showed adhesions of wall of jejunum. The
multiple irregular hypointensity areas were observed in the mass
and considered to be necrotic areas (white arrow).received 2 courses of chemotherapy with vincristine,
ifosfamide, and adriamicin. The patient was on regular
follow-up for 6 months after chemotherapy, there was no
sign of recurrence of tumor found in this period.
Material and methods
On macroscopical examination, the lesion was gray-tan
solitary nodular mass with necrotic areas, measuring
10.0 × 8.5 cm, was located in the mesentery of small intes-
tine. The mass was poorly circumscribed and there was no
fibrous capsule round the mass. A part of tumor was ob-
served to extend to the wall of jejunum and some enlarged
mesenteric lymph nodes were also observed (Figure 2).
The tumor was routinely fixed in 10% neutral buffered for-
malin and the tissues were embedded in paraffin. Four mi-
crometer-thick sections were stained with Hematoxylin
and Eosin (HE). Immunohistochemical analyses were
performed using the ChemMate Envision/HRP Kit (Dako,
Glostrup, Denmark). The antibodies used in this study
were cytokeratin (AE1/AE3), epithelial membrane antigen
(EMA), vimentin, S-100 protein, HMB-45, Melan-A,
neuron-specific enolase (NSE), synaptophysin (Syn), chro-
mogranin A (CgA), CD34, CD117, Dog-1, smooth muscle
actin (SMA), desmin, Myo-D1, CD68, CD99 and Ki-67.
Pathological findings
Under microscopic examination, a part of the tumor was
surrounded by a thin fibrous pseudocapsule at the per-
iphery. The tumor was composed of cells with abundant
clear to fine eosinophilic granular cytoplasm and round,Figure 2 Gross examination of resected mesenteric mass. The
mass was gray-tan solitary nodular mass without a fibrous capsule.
The mass was observed to extend to the wall of jejunum and
necrotic areas were also found.
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delicate vascular septa. Most of tumor cells appeared to
have bland cytologic features. However, in some areas,
the cells became more epithelioid, and nuclei varied in
size and shape, with dispersed chromatin and prominent
nucleoli. Mitoses were present with mitotic rate of 2/50
high power fields. There was extensive coagulative necro-
sis and hemorrhage but neither adipocytes nor thick-
walled blood vessels were observed in the tumor. The
tumor cells appeared to have infiltrated into the under-
lying smooth muscle of jejunum but there were no
features of vascular invasion. One of enlarged lymph
nodes of mesentery was found to be involved by tumor
(Figure 3A-D). Immunohistochemically, the tumor cells
were stained positive for HMB-45, Melan-A, NSE, CD68
and calponin (focal and weakly), but were negative for
S-100 protein, Syn, CgA, cytokeratin (AE1/AE3), EMA,Figure 3 Photomicrographs of the mesenteric mass. (A) At lower powe
cells with clear to eosinophilic cytoplasms. The epithelioid tumor cells were
had round to oval vesicular nuclei with 1-2 centrally located small nucleoli,
(C) Extensive necrotic areas were observed in the tumor. Note the atypical
necrosis. (D) One of enlarged mesenteric lymph nodes was observed to be
mesenteric mass showed epithelioid tumor cells were diffusely positive for
staining with original magnification × 200; B, H&E staining with original ma
E-F, Immunohistochemical staining with original magnification, ×400).CD34, CD117, Dog-1, SMA, desmin, Myo-D1 and CD99.
Ki-67 was positive in 3% of tumor cells (Figure 3E-F).
Based on the pathological findings, the mesenteric mass
was diagnosed as malignant perivascular epithelioid cell
tumor with lymph node involvement.
Conclusions
Perivascular epithelioid cell tumor (PEComa) is a mesen-
chymal tumor composed chiefly of perivascular epithelioid
cell (PEC). PEC was first described in 1994 by Bonetti et al.
to introduce the concept of a family of tumor that was
characterized by the presence of a peculiar muscle cell that
expressed melanoma-associated antigens such as HMB-45
and HMSA-1 [7]. The term PEComa was coined by
Zamboni et al. in 1996 to describe this rare family of lesions
[1]. In 2002, the World Health Organization accepted the
designation PEComa as a distinct mesenchymal neoplasmr field, the tumor was observed to be composed of epithelioid tumor
arranged around delicate vasculature. (B) The epithelioid tumor cells
and mitotic figure was observed in the tumor cells (black arrow).
tumor cells with irregular hyperchromatic nuclei at the periphery of
involved by tumor cells. Immunohistochemical analysis of the
melanocytic markers, HMB-45 (E) and Melan-A (F). (A and C, H&E
gnification × 400; D, H&E staining with original magnification × 100;
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unique PECs [8]. The histogenesis and cytogenetics of
PEComa are largely unknown. Until recently, there has
been no known normal counterpart of PEC. Bonnetti et al.
hypothesized that PEC can modulate its morphology and
immunophenotype. They believe that the PEComa is com-
posed of PECs in different stages of modulation with con-
sistent reactivity for melanoma-associated markers, variable
reactivity for muscular markers, and nonreactivity for epi-
thelial markers [7]. Although a few researchers still doubt
the existence of this entity due to the overlapping morpho-
logic and immunologic features with smooth muscle
tumors and the absence of a normal counterpart for PEC,
the increasing genetic evidence has shown PEComa to be a
distinct type of neoplasm [9,10].
PEComas have been found in various organs and have a
tendency to affect women with approximately 40% of tu-
mors originated from the uterus [2], although some un-
usual sites can be also involved occasionally, such as
vagina [11], orbit [12], small and large bowel [13], heart
[14] prostate [15], bladder [16] and endometrium [17].
Multifocal PEComas (PEComatosis) have been described
in the literature [18]. Mesenteric PEComas are rare with
only 6 cases described in the literature so far [3-5]
(Table 1). The ratio of mesenteric PEComa incidence in
women and men is 2:1. 4 of 6 cases were considered to be
malignant PEComa with tissue invasion and the tumors
recurred within 6-22 months, although two cases received
concurrent chemoradiotherapy after surgical resection.
None of previously reported mesenteric PEComas has
lymph node involvement. To our best knowledge, our pre-
senting case is the first one of mesenteric malignant
PEComa with lymph node involvement, although the
cytologic appearance of tumor cells is relatively bland.
Due to their rarity, the criteria for the diagnosis of ma-
lignancy have not yet been fully established. Some types of
PEComa family, such as AML and epithelioid AML of
kidney, have been infrequently reported to have metastasis
to lymph nodes or extra-renal sites, but regional lymph
node involvement and vascular invasion were considered
to represent a multifocal growth pattern rather than me-
tastasis [19]. Among adverse pathologic parameters in
AMLs, including cellularity, high nuclear grade and mi-
totic figures, none correlate with outcome, although tu-
mors with necrosis, mitotic activity, nuclear anaplasia and
extra-renal spread should raise significant concern for ma-
lignant outcome. In fact, we are not sure the lymph node
involvement of the current case representing a multifocal
growth pattern or metastasis so far. Folpe et al. proposed
provisional criteria for PEComas of soft tissue and
gynecoelogic origin in 2005 [3]. In these diagnostic cri-
teria, PEComas were classified into “benign,” “of uncertain
malignant potential,” and “malignant” categories. There
were 6 histological features indicative of high risk: tumorsize >5 cm, infiltrative pattern, high nuclear grade and cel-
lularity, high mitotic rate (>1/50 HPF), necrosis, and vas-
cular invasion. Small PEComas (<5 cm) without any of the
6 high-risk features were most likely to be benign. Large
PEComas (>5 cm) without any other features had uncer-
tain malignant potential. PEComas with 2 or more high-
risk features should be considered malignant. In 2008,
Fadare et al. suggested that the only features that indicate
a definite potential for aggressive behavior were a mitotic
count >1/10 HPF and/or coagulative necrosis, while cyto-
logic atypia should be considered to be at least an indica-
tion of uncertain malignant potential. The size of tumors
was not advised to distinguish malignancy or non-
malignant PEComas [6]. The regional lymph node in-
volvement was not considered to be a worrisome histo-
logic feature in both criteria. The present case was
considered to be a malignant PEComa, because the tumor
had the most of worrisome histologic features presented
either by Folpe or by Fadare. However, it has revealed that
malignant PEComa with frankly unfavorable morpho-
logical features have an indolent clinical course even in
the presence of lymph node involvement [20]. Recent
studies have also demonstrated that random X chromo-
some inactivation could be detected in various involved
lymph nodes, supporting the hypothesis of a multifocal
disease rather than a metastatic tendency [20]. Due to the
limited case numbers and the short follow-up period,
we could not define prognostic factors for malignant
PEComa. However, combined with previously reported
PEComas with malignant features [4,5,15,20,21], we con-
sider that malignant PEComas should be highly aggressive
in biological behavior. Therefore, infiltrating growth pat-
tern and extensive coagulative necrosis should be more
important factors to be used for malignant evaluation
because they represent the aggressiveness in biological
behavior of this tumor. Hypercellularity, high or atypical
mitotic figures, and even regional lymph node involve-
ment might not indicate the overt malignancy of
this tumor.
The microscopic morphology of the present case was
characterized by epithelioid tumor cells with abundant
clear cytoplasm arranged in nests or wide fascicles with
delicate vascular septa. These morphological appearances
may pose a diagnostic dilemma, especially in unusual loca-
tions. A differential diagnosis of PEComa in soft tissue
usually includes clear-cell sarcoma of soft tissue (also
known as “malignant melanoma of soft parts”), alveolar
soft part sarcoma and epithelioid leiomyosarcoma. How-
ever, PEComas differential diagnosis in the mesentery
should mainly include epithelioid leiomyosarcoma, epithe-
lioid extra-gastrointestinal stromal tumor (extra-GIST)
and metastatic clear-cell renal cell carcinoma. Although
PEComas and clear-cell sarcoma of soft tissue share some
phenotypic features, including positive reactivity to the











Invasion Necrosis LN status Treatment Outcome
1 Folpe AL (2005) [3] PEComa with UMP 67/Female 13.0 High Moderate 0 No No Not involved SE only NED at
84 months
2 Benign PEComa 97/Female 4.0 Intermediate Moderate 0 No No Not involved SE only NED at
38 months
3 Malignant PEComa 80/Female 9.5 High High >50 Vascular invasion Yes Not involved SE only NED at
19 months
4 Malignant PEComa 46/Female 12.0 Intermediate Moderate 5 Vascular invasion Yes Not involved SE + CT Recur and liver
metastases at
22 months;
die at 27 months
5 Gross E (2010) [4] Malignant PEComa 5.5/Male 5.0 High Moderate NA Surrounding
tissue invasion
No Not involved SE only NED at
24 months
6 Lai CL (2012) [5] Malignant PEComa 59/Male 11.0 High High 3 Vascular invasion Yes Not involved SE + CT Recur at
6 months; alive
7 The present case Malignant PEComa 38/Female 10.0 Intermediate Moderate 2 Surrounding
tissue invasion
Yes Involved SE + CT NED at
6 months
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coma of soft tissue exhibits dense fibrous septae rather
than the delicate vascular-rich stroma of the PEComas. In
addition, clear-cell sarcoma of soft tissue always shows
S-100 protein positivity, which is usually absent in
PEComa. Alveolar soft part sarcoma is a rare tumor com-
posed of large, uniform, epithelioid cells having abundant
eosinophilic, granular cytoplasm arranged in solid nests
and/or alveolar structures, separated by thin, sinusoidal
vessels, which may cause diagnostic confusion with
PEComas. However, alveolar soft part sarcoma has no
consistently immuno-positive findings, particularly it is
negative for melanocytic markers. Epithelioid leiomy-
osarcoma may share histologic features of PEComas: both
tumors are composed of spindle and/or epithelioid cells
with variable reactivity for smooth muscle markers, such
as SMA, calponin and H-caldesmon. However, leiomyo-
sarcomas show negative staining for melanocytic markers.
In addition, PEComa is readily differentiated from epitheli-
oid extra-GIST and metastatic clear-cell renal cell
carcinoma by positive immunohistochemical staining for
Melan-A and HMB-45 and negative staining for both
CD117, Dog-1, CD34 and pan-cytokeratin (AE1/AE3).
Effective therapies for PEComas have yet to be
established and the management of PEComas is quite
variable. Surgical excision is the most common approach
for PEComa but adjuvant chemo- or radio-therapy, even
hormone therapy has also been advised for all patients
with malignant features. However, due to the rarity of the
disease and the difficulty in predicting the malignant be-
havior, the benefit of those adjuvant therapies is still ques-
tionable. In our case, the patient received 2 courses of
chemotherapy after surgery, and there was no sign of re-
currence of tumor found in short follow-up period. How-
ever, close clinical surveillance accompanied by imaging
examination should be recommended to inspect the local
recurrence and distant metastasis of this tumor.
In conclusion, we reported herein an unusual case of
mesenteric PEComa occurring in a middle-aged patient
with regional lymph node involvement. Although the cy-
tologic appearance of tumor cells was relatively bland, the
infiltrating growth pattern and extensive coagulative ne-
crosis should be indicative malignancy. We consider that
marked hypercellularity, active mitotic figures, and even
regional lymph node involvement observed merely in
tumor might not represent a distinctive sign of malignant
PEComa. However, this postulate should be further inves-
tigated by more such cases with long-term follow up.
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